BIO-TECHNE Corp (TECH) · Sep 23, 2026 · Acquisition

Bio-Techne clears Merck vote, but closing still awaits approvals

Merger approved — Shareholder approval obtained; closing targeted for late 2026 or early 2027

Bio-Techne shareholders approved Merck KGaA’s $73-per-share acquisition, removing a key condition while regulatory approvals and closing remain ahead.

Bio-Techne is a life-science tools and diagnostics supplier pursuing growth across research, spatial biology, cell and gene therapy, and precision diagnostics; its standalone strategy has centered on expanding differentiated products and adjacent markets through innovation and acquisitions. Merck’s proposed purchase would fold that platform into a much larger life-science organization for $73 per share in cash, or roughly $11.3 billion of enterprise value.

The shareholder hurdle is cleared, but this is a milestone—not a completed deal. Bio-Techne said shareholders approved and adopted the merger agreement. 〔0〕 The Hart-Scott-Rodino waiting period also expired on September 18, 2026. 〔1〕 That removes two important process risks, but the vote and antitrust clearance were already expected parts of the announced transaction, so the filing mainly reduces execution uncertainty rather than changing the strategic story.

The remaining risk is concentrated in regulatory clearance and closing execution. The company still expects completion by late 2026 or early 2027, subject to customary conditions and remaining required approvals. 〔2〕 The filing therefore advances the deal toward completion, while leaving the core timing and integration questions unresolved.

Bottom line: This is a clean approval milestone for an already-announced acquisition, not a new strategic surprise. It makes Merck’s purchase of Bio-Techne more executable, but the transaction still depends on remaining regulatory sign-offs and closing conditions.

What to watch next

Remaining regulatory approvals and transaction closing, late 2026 or early 2027

Original filing on SEC EDGAR

More BIO-TECHNE Corp news

Bio-Techne clears Merck vote, but closing still awaits approvals | TECH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.